Jing Xu

Jing Xu, Ph.D, currently serves as an Investment Principal at LYFE Capital since January 2020 and holds several roles in various organizations, including Board Member at ChemLex and Starna Therapeutics, and Board Observer at MediLink Therapeutics, all from 2022. Previously, Jing Xu was a Board Member at Sciwind Biosciences and worked at Amgen as Business Development Lead and Product Launch Lead from September 2018 to January 2020. Other prior experience includes Associate Director of Corporate Development and Investments at WuXi AppTec and Management Consultant at IMS Consulting Group. Additional experience comprises a teaching fellowship at Teach For China and a pharmaceutics co-op at Genzyme. Jing Xu earned a Ph.D in Pharmaceutical Sciences from Northeastern University and holds degrees from The University of Georgia and Nanjing University.